Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702-StaMINA Trial)

被引：0
|
作者：
Stadtmauer, Edward A.
Pasquini, Marcelo C.
Blackwell, Beth
Knust, Kristin
Bashey, Asad
Devine, Steven M.
Efebera, Yvonne A.
Ganguly, Siddhartha
Gasparetto, Cristina
Geller, Nancy
Giralt, Sergio A.
Hari, Parameswaran
Horowitz, Mary M.
Koreth, John
Landau, Heather
McCarthy, Philip L.
McClune, Brian
Nelson, Courtney
Qazilbash, Muzaffar H.
Shah, Nina
Vesole, David H.
Vij, Ravi
Vogl, Dan T.
Somlo, George
Krishnan, Amrita
机构：
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
LBA-1
引用
收藏
页数：4
相关论文
共 6 条
  • [1] Post Autologous Transplant (autoHCT) Therapies in High Risk MM. Subgroup analysis of Phase III BMTCTN 0702 STAMINA: autoHCT Followed by Lenalidomide Maintenance(Len)(AM) vs auto HCT and Len and Bortezomib (BZ) and Dexamethasone Consolidation Len Maintenance(ACM) vs Tandem autoHCT Len Maintenance
    Krishnan, Amrita
    Pasquini, Marcelo
    Blackwell, Beth
    Knust, Kristin
    Bashey, Asad
    Devine, Steven
    Efebera, Yvonne
    Ganguly, Siddhartha
    Gasparetto, Cristina
    Geller, Nancy
    Giralt, Sergio
    Parameswaran, Hari
    Horowitz, Mary
    Koreth, John
    Landau, Heather
    McCarthy, Philip
    McClune, Brian
    Nelson, Courtney
    Qazilbash, Muzaffar
    Shah, Nina
    Vesole, David
    Vij, Ravi
    Vogl, Dan T.
    Somlo, George
    Stadtmauer, Edward
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E5 - E5
  • [2] Response status as predictor of survival after autologous hematopoietic cell transplant (AHCT), without or with consolidation (with bortezomib, lenalidomide (Len) and dexamethasone) and len maintenance (AM vs. ACM) versus tandem AHCT and len maintenance (TAM) for up-front treatment of patients (pts) with multiple myeloma (MM): BMT CTN0702-stamina (NCT01109004)
    Somlo, Beorge
    Pasquini, Marcelo C.
    Blackwell, Heti
    Devine, Steven Michael
    Ganguly, Siddhartha
    Efebera, Yvonne
    Giralt, Sergio
    Hari, Parameswaran
    Koreth, John
    Landau, Heather Jolie
    McClune, Brian L.
    Quazilbash, Mussafar
    McCarthy, Philip L.
    Shah, Nina
    Vesole, David H.
    Vij, Ravi
    Vogl, Dan T.
    Krishnan, Amrita Y.
    Stadtmauer, Edward A.
    Geller, Nancy
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Evaluation of Tumor Vaccine Generation in a Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant (AutoHCT)Followed By Lenalidomide Maintenance for Multiple Myeloma (MM) with or without Vaccination with Dendritic Cell/ Myeloma Fusions (DC/MM fusion vaccine): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1401
    Avigan, David E.
    Shah, Nina
    Logan, Brent
    Zhu, Jiaxi
    Bisharat, Lina
    Callander, Natalie S.
    Chodon, Thinle
    Dhakal, Binod
    Efebera, Yvonne A.
    Geller, Nancy
    Hematti, Peiman
    Herman, Michele
    Lazarus, Hillard M.
    McKenna, David H., Jr.
    Nelson, Courtney
    Nooka, Ajay
    O'Brien, Kelly
    O'Donnell, Lynn C.
    Rapoport, Aaron P.
    Rosenblatt, Jacalyn
    Soiffer, Robert J.
    Stroopinsky, Dina
    Torka, Pallawi
    Uhl, Lynne
    Waller, Edmund K.
    Wu, Juan
    Young, James W.
    Pasquini, Marcelo C.
    Chung, David J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S62 - S63
  • [4] The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302).
    Nishihori, Taiga
    Bashir, Qaiser
    Pasquini, Marcelo C.
    Martens, Michael
    Wu, Juan
    Alsina, Melissa
    Efebera, Yvonne Adeduni
    Gasparetto, Cristina
    Geller, Nancy
    Giralt, Sergio
    Koreth, John
    McCarthy, Philip L.
    Scott, Emma Catherine
    Stadtmauer, Edward Allen
    Vesole, David H.
    Hari, Parameswaran
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Tandem Autologous Stem Cell Transplants (auto-auto) With or without Maintenance Therapy Versus Single Autologous Transplant Followed by HLA-Matched Sibling Non- Myeloablative Allogeneic Stem Cell Transplant (auto-allo) for Patients (pts) with High Risk (HR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0102 Trial
    Stadtmauer, Edward A.
    Krishnan, Amrita
    Pasquini, Marcelo C.
    Ewell, Marian
    Alyea, Edwin P., III
    Antin, Joseph H.
    Castro-Malaspina, Hugo
    Kassim, Adetola A.
    Negrin, Robert
    Qazilbash, Muzaffar H.
    Rizzo, J. Douglas
    Rowley, Scott D.
    Sahebi, Firoozeh
    Somlo, George
    Vesole, David H.
    Vogl, Dan T.
    Weisdorf, Daniel J.
    Geller, Nancy
    Horowitz, Mary M.
    Maloney, David G.
    Giralt, Sergio
    BLOOD, 2010, 116 (21) : 233 - 234
  • [6] Tandem Autologous Hematopoietic Stem Cell Transplants (AuHCT) with or without Maintenance Therapy (auto-auto) Versus Single AuHCT Followed by HLA Matched Sibling Non- Myeloablative Allogeneic HCT (auto-allo) for Patients with Standard Risk (SR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial
    Krishnan, Amrita
    Pasquini, Marcelo C.
    Ewell, Marian
    Stadtmauer, Edward A.
    Alyea, Edwin P., III
    Antin, Joseph H.
    Comenzo, Raymond L.
    Goodman, Stacey
    Hari, Parameswaran
    Negrin, Robert
    Qazilbash, Muzaffar H.
    Rowley, Scott D.
    Sahebi, Firoozeh
    Somlo, George
    Vesole, David H.
    Vogl, Dan T.
    Weisdorf, Daniel J.
    Geller, Nancy
    Horowitz, Mary M.
    Giralt, Sergio
    Maloney, David G.
    BLOOD, 2010, 116 (21) : 24 - 25
1